Stay updated with breaking news from Aim Immunotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AIM ImmunoTech (NYSE:AIM – Get Free Report) will issue its quarterly earnings data on Tuesday, April 2nd. AIM ImmunoTech Trading Up 6.3 % Shares of NYSE AIM opened at $0.47 on Monday. AIM ImmunoTech has a one year low of $0.32 and a one year high of $0.75. The firm has a market capitalization of […]
AIM ImmunoTech (NYSE:AIM – Get Free Report) and Poseida Therapeutics (NASDAQ:PSTX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation. Insider and Institutional Ownership 12.8% of AIM […]
AIM ImmunoTech (NYSE:AIM – Get Free Report) and Poseida Therapeutics (NASDAQ:PSTX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations. Earnings & Valuation This table compares AIM […]
AIM ImmunoTech Inc. (NYSE:AIM – Get Free Report) CEO Thomas K. Equels purchased 33,861 shares of the business’s stock in a transaction that occurred on Monday, November 27th. The stock was bought at an average cost of $0.44 per share, with a total value of $14,898.84. Following the acquisition, the chief executive officer now owns […]
AIM ImmunoTech Inc. (NYSE:AIM – Get Free Report) CEO Thomas K. Equels purchased 33,861 shares of the company’s stock in a transaction dated Monday, November 27th. The stock was purchased at an average price of $0.44 per share, with a total value of $14,898.84. Following the transaction, the chief executive officer now owns 640,697 shares […]